Recharging aged-CAR with NAD⁺ to boost immunotherapy

Impaired cellular metabolism contributes to the age-related decline in T cell function, undermining the response to immunotherapy in older patients with cancer. In a recent study, Hope et al. report that a reduction in intracellular NAD⁺ levels compromises metabolic fitness and drives immunosenescence. Notably, restoring NAD⁺ levels can reverse age-related chimeric antigen receptor (CAR)-T deterioration, suggesting a promising 'metabolic immunotherapy' that widely benefits older patients with cancer.